Explore comprehensive CDMO services offered by Fujifilm Biotechnologies, supporting end-to-end Anlaytical Testing, Drug Development and Manufacturing. Fujifilm Biotechnologies enables faster, compliant, and scalable pharma innovation tailored to your needs.
Country: Denmark, Japan, U.S.A., United Kingdom
Description: Fujifilm Biotechnologies is the new name for the global biopharmaceutical CDMO previously known as Fujifilm Diosynth Biotechnologies, rebranded in mid-2025 as part of Fujifilm’s Life Sciences Group alignment. The company provides end-to-end biologics, vaccines, and advanced therapy manufacturing services across all development stages—from preclinical and process development to commercial supply. Fujifilm Biotechnologies operates a global network of over 4,800 employees, with major facilities in the United States (North Carolina, Texas, California, Massachusetts), the United Kingdom (Billingham, Teesside), and Denmark (Hillerød). It specializes in biologics manufacturing using microbial, mammalian, and viral systems and provides integrated CDMO services including cell line development, process and analytical development, and large-scale GMP manufacturing. - Show More
